MiNK Therapeutics, Inc. (INKT) Investor Relations Documents

MiNK Therapeutics, Inc. (INKT) investor relations documents from the company's IR site: 40 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-13Press releaseMiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial o
2026-08-06Press releaseMiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury,
2026-08-06Press releaseMiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Sym
2026-06-03Press releaseMiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
2026-05-28Press releaseMiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critic
2026-05-20Press releaseMiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clin
2026-05-15Press releaseMiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized C
2026-05-14Press releaseMiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung
2026-05-12Press releaseMiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Im
2026-05-08Press releaseMiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therap
2026-04-17Press releaseMiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal
2026-04-03Press releaseMiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gas
2026-04-02Press releaseMiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy
2026-04-01Press releaseMiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 Internation
2026-03-31Press releaseMiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum
2026-03-17Press releaseMiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across
2026-03-10Press releaseMiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cance
2026-02-03Press releaseMiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pu
2026-01-08Press releaseMiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-7
2025-05-05Press releaseMiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
2024-12-18Press releaseMiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
2024-09-03Press releaseMiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference
2024-05-14Press releaseMiNK Reports First Quarter 2024 Results
2024-04-30Press releaseMiNK to Provide Corporate Update and First Quarter 2024 Financial Report
2024-03-21Press releaseMiNK Reports Fourth Quarter and Year-End 2023 Results
2024-03-07Press releaseMiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
2023-11-09Press releaseMiNK Therapeutics Reports Third Quarter 2023 Results
2023-10-30Press releaseMiNK to Provide Third Quarter 2023 Financial Report and Corporate Update
2023-08-10Press releaseMiNK Therapeutics Reports Second Quarter 2023 Results
2023-07-28Press releaseMiNK to Provide Second Quarter 2023 Financial Report and Corporate Update
2023-05-11Press releaseMiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results
2023-04-27Press releaseMiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results
2023-03-21Press releaseMiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
2023-03-07Press releaseMiNK Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results
2022-11-03Press releaseMiNK Therapeutics Reports Corporate Update and Third Quarter 2022 Financial Results
2022-10-20Press releaseMiNK Therapeutics to Report Third Quarter 2022 Financial Results and Business Update
2022-08-09Press releaseMiNK Therapeutics Reports Corporate Update and Second Quarter 2022 Financial Results
2022-07-27Press releaseMiNK Therapeutics to Report Second Quarter 2022 Financial Results and Business Update
2022-05-10Press releaseMiNK Therapeutics Corporate Update and First Quarter 2022 Financial Report
2022-04-27Press releaseMiNK Therapeutics to Report First Quarter 2022 Financial Results and Business Update

INKT overview · INKT earnings · INKT financials · INKT KPIs · INKT ownership · INKT peers · INKT filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.